Medtronic (NYSE: MDT) announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now ...

Two multicenter trials drew different conclusions about the value of conduction system relative to biventricular pacing for left bundle branch block in heart failure.

Please provide your email address to receive an email when new articles are posted on . Long-term CRT-D use was tied to improved survival and time to adverse events vs. ICD therapy in patients with ...

A 173-patient randomized trial in HFrEF (LVEF ≤35%) with LBBB (QRS ≥130 ms) showed CSP was inferior to BiVP for a hierarchical 12‑month composite endpoint. Worse outcomes with CSP were reflected by an ...

A made-in-Calgary 4D heart model is transforming treatment for heart failure patients having a specialized pacemaker inserted, called cardiac ...

Sarasota Memorial Hospital is part of a global research effort on an option to traditional cardiac resynchronization therapy.

SUNNYVALE, Calif.--(BUSINESS WIRE)--EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that the U.S. Food and Drug Administration (FDA) ...

AdaptivCRT® Algorithm Customizes Therapy for Heart Failure Patients and Improves Their Response Rates MINNEAPOLIS - Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval ...

Results from the Cardiac Resynchronization—Heart Failure (CARE-HF) study support the use of implantable cardiac-resynchronization devices in patients with heart failure due to left-ventricular ...

Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc ...

MINNEAPOLIS - Medtronic, Inc. today announced CE (Conformité Européenne) Mark receipt and the European launch of its newest cardiac resynchronization therapy-pacemaker, Viva® CRT-P. The Viva CRT-P is ...